Evidence map›Paper›PMID 35923804›Full record

ArticleFrontiers in cellular and infection microbiology2022

Evidence of Neutralizing and Non-Neutralizing Anti-Glucosaminidase Antibodies in Patients With

Shardulendra Prasad Sherchand, Rajan P Adhikari, Gowrishankar Muthukrishnan, Tulasikumari Kanipakala, John R Owen, Chao Xie, M Javad Aman, Richard A Proctor, Edward M Schwarz, Stephen L Kates

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Shardulendra Prasad SherchandIntegrated BioTherapeutics, Inc., Rockville, MD, United States.
Rajan P AdhikariIntegrated BioTherapeutics, Inc., Rockville, MD, United States.
Gowrishankar MuthukrishnanCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, United States.
Tulasikumari KanipakalaIntegrated BioTherapeutics, Inc., Rockville, MD, United States.
John R OwenDepartment of Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, United States.
Chao XieCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, United States.
M Javad AmanIntegrated BioTherapeutics, Inc., Rockville, MD, United States.
Richard A ProctorDepartments of Medical Microbiology/Immunology and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Edward M SchwarzCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, United States.
Stephen L KatesDepartment of Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, United States.
Integrated BioTherapeutics (United States) · USUniversity of Rochester Medical Center · USVirginia Commonwealth University · USUniversity of Wisconsin–Madison · US

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Project 2: Defining the Protective vs. Susceptible Immune Proteome of S. aureus OsteomyelitisP50AR072000 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2017 to 2026
$13.6M
Rochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application)P30AR069655 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2016 to 2026
$7.8M
Immunotherapy of MRSA OsteomyelitisR44AI155309 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD · 2021 to 2023
$3.0M
Diagnosis and Tracking of Spinal Staphylococcus aureus Orthopaedic Implant InfectionsR21AI169736 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ACKERT-BICKNELL, CHERYL LYNNE, MUTHUKRISHNAN, GOWRISHANKAR · 2022 to 2023
$439k
NCATS NIH HHS UL1 TR002649NIAID NIH HHS R44 AI155309NIAMS NIH HHS P30 AR069655NIAMS NIH HHS P50 AR072000
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Methicillin-Resistant Staphylococcus aureusOsteomyelitisStaphylococcal InfectionsAnimalsAntibodies, NeutralizingHexosaminidasesHumansPilot ProjectsProspective StudiesStaphylococcus aureusAntibodies, NeutralizingHexosaminidasesantibodiesglucosaminidaseimmunoassayosteomyelitisStaphylococcus aureus

Identifiers

PMID35923804
PMCPMC9339635
OpenAlexW4285730520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.